#USA #Fremont #Ultima Genomics #UG200 Series #Solaris 2.0

Ultima Genomics Unveils the Next Era of Sequencing with UG200 Series

Ultima Genomics, a frontrunner in ultra-high-throughput sequencing technology, has recently introduced the UG200 Series along with next-generation Solaris 2.0 workflows. This new offering aims to revolutionize genomic sequencing by delivering remarkably higher output, enhanced performance, and flexible wafer configurations at a competitive price. The UG200 Series represents a significant leap in sequencing capabilities, setting the stage for groundbreaking developments in biology and genomic research.

At the core of the UG200 Series are two innovative configurations: the UG200 and the UG200 Ultra. These systems promise to almost double the output compared to the previous UG100® model, offering up to 20 billion reads per wafer. This capability is paired with a reduction in runtime and operational footprints, fostering improved usability and allowing seamless integration into existing laboratory workflows.

Key Features of the UG200 Series

The UG200 Ultra is designed with dual-wafer capabilities, allowing for the sequencing of over 60,000 whole genomes per year at a 30x coverage. This model boasts exceptional throughput and flexibility, suited for labs handling significant sequencing volumes. Priced at $1,250,000, it offers advanced computational features to support faster data rates. Additionally, a benchtop liquid handler for Solaris 2.0 amplification is available for $125,000 for labs looking to enhance their automation capabilities.

On the other hand, the UG200 single-wafer platform is priced as low as $850,000. This configuration is designed to offer immediate deployment options while maintaining scalability for future needs. It can be upgraded to the Ultra version through an in-field upgrade, ensuring compatibility as lab demands evolve.

Advancements in Solaris 2.0 Workflows

Alongside the UG200 Series, Ultima has introduced Solaris 2.0 workflows that leverage next-generation amplification technology to enhance genomic coverage and performance significantly. These advancements permit improved uniformity, particularly in complex genomic regions, and allow for liquid biopsies with extreme accuracy.

The Solaris 2.0 system streamlines the amplification process by eliminating the need for a separate ePCR station, allowing more efficient sample handling directly within the existing lab setup. These workflows are designed to meet the needs of diverse applications while maintaining Ultima's renowned SNVQ-60 accuracy, further pushing the boundaries of genomic capabilities.

Future-Proofing Sequencing Technology

In a bid to support existing UG100 customers, Ultima plans to make Solaris 2.0 compatible with earlier models, allowing upgrades to harness the advantages of the latest workflows. Customers can migrate to the UG100 Plus to experience up to four times more annual output compared to their initial UG100 capabilities.

Customer Testimonials Reflecting Success

Prominent genomics organizations have already begun to integrate Ultima's sequencing solutions with notable success. For instance, Macrogen has reported the effective implementation of Ultima sequencing in extensive single-cell projects, while other companies like Gene by Gene and the Sanger Institute have praised the reliability and efficiency of the new systems.

Dr. Arjan Bormans from Gene by Gene remarked on the ease of transition and the advantages provided by the smaller footprint and quick turnaround times of the new system. Meanwhile, Dr. Carl Anderson of the Wellcome Sanger Institute highlighted the significant role these innovations have in generating impactful datasets for further biological research.

The UG200 Series will be showcased at the upcoming Advances in Genome Biology and Technology (AGBT) Conference, marking Ultima’s continued commitment to advancing genomic sequencing technology at scale. With their vision to facilitate global genomics accessibility and applications like comprehensive cancer monitoring and population-scale genomics, Ultima Genomics is undoubtedly pioneering the next wave of genomic innovation.

Conclusion

Ultima Genomics is carving a path toward the future of sequencing technology with the UG200 Series and Solaris 2.0 workflows. As the demand for genomic data increases across various sectors, their dedication to expanding capabilities and reducing costs is vital for unlocking the potential of genomics in research and clinical settings alike. With ongoing advancements, Ultima aims to maintain its leading role in an ever-evolving landscape of genomic exploration.